Evidence map›Paper›PMID 37306625›Full record

ArticlemBio2023

EFdA efficiently suppresses HIV replication in the male genital tract and prevents penile HIV acquisition.

Martina Kovarova, Sarah E Wessel, Claire E Johnson, Shelby V Anderson, Mackenzie L Cottrell, Craig Sykes, Myron S Cohen, J Victor Garcia

Open access · goldAbstract read
In one paragraph

Article in mBio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Martina KovarovaInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina, USA.ORCID 0000-0001-7152-1709
Sarah E WesselInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina, USA.
Claire E JohnsonInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina, USA.
Shelby V AndersonInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina, USA.
Mackenzie L CottrellUNC Eshelman School of Pharmacy , Chapel Hill, North Carolina, USA.
Craig SykesUNC Eshelman School of Pharmacy , Chapel Hill, North Carolina, USA.
Myron S CohenInstitute for Global Health and Infectious Diseases, University of North Carolina , Chapel Hill, North Carolina, USA.
J Victor GarciaInternational Center for the Advancement of Translational Science, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina, USA.ORCID 0000-0003-3726-0482
University of North Carolina at Chapel Hill · USUniversity of North Carolina Health Care · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI126619 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARGOLIS, DAVID M. · 2016 to 2020
$23.2M
Next generation ultra-long acting antiretroviral formulations for HIV treatment and preventionR01AI140799 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GARCIA-MARTINEZ, J. VICTOR · 2018 to 2022
$3.9M
Impact of the gastrointestinal microbiome on HIV reservoirsR01DK131585 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI J. Victor Garcia-Martinez, Ryan B Sartor · 2021 to 2026
$3.4M
Development and pre-clinical evaluation of a novel Polymer-Based In-Situ Forming Implant (ISFI) for Long-Acting HIV PrEPR01AI131430 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BENHABBOUR, SOUMYA RAHIMA, KOVAROVA, MARTINA · 2017 to 2020
$2.4M
NCI NIH HHS P30 CA016086NIAID NIH HHS P30 AI050410NIAID NIH HHS R01 AI131430NIAID NIH HHS R01 AI140799NIAID NIH HHS UM1 AI126619NIDDK NIH HHS R01 DK131585
6 · The paper itself

Abstract

Sexually transmitted HIV infections in heterosexual men are acquired through the penis. Low adherence to condom usage and the fact that 40% of circumcised men are not protected indicate the need for additional prevention strategies. Here, we describe a new approach to evaluate the prevention of penile HIV transmission. We demonstrated that the entire male genital tract (MGT) of bone marrow/liver/thymus (BLT) humanized mice is repopulated with human T and myeloid cells. The majority of the human T cells in the MGT express CD4 and CCR5. Direct penile exposure to HIV leads to systemic infection including all tissues of the MGT. HIV replication throughout the MGT was reduced 100-1,000-fold by treatment with 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA), resulting in the restoration of CD4

Indexed as

HIV InfectionsAnimalsBone MarrowCD4-Positive T-LymphocytesHumansMaleMicePenisVirus ReplicationEFdAHIV pathogenesisHIV preventionHIV treatmenthuman immunodeficiency virusmale genital tractpenile infectionstem cells

Identifiers

PMID37306625
PMCPMC10470584
OpenAlexW4380291632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.